Antiviral drugs market is set to reach US$ 127 billion by 2035, North America leads the market with 43% market share.

The global Antiviral drugs market size is estimated to grow from USD 68.94 billion in 2025 to reach USD 73.78 billion in 2026 and USD 127 billion by 2035, representing a higher CAGR of 6.4% during the forecast period 2026 to 2035.

DataM Intelligence unveils its latest report on the "Antiviral drugs Market size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies aiming to stay ahead in the competitive Market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/antiviral-drugs-market?pratik

United States: Key Industry Developments (2025)

✅ September 2025: Shionogi's New Drug Application (NDA) for oral antiviral ensitrelvir designed to prevent COVID‐19 after exposure was accepted for FDA review, setting a PDUFA target action date in mid‐2026 and positioning it as a potential first‐of‐its‐kind prophylactic therapy.

✅ June 2025: The U.S. FDA approved lenacapavir (brand name Yeztugo), a twice‐yearly injectable antiviral for HIV prevention in adults and adolescents, marking a major shift from daily regimens to long‐acting prophylaxis.

✅ April 2025: Gilead Sciences launched "Viracor," a next‐generation antiviral targeting multi‐drug‐resistant HIV, featuring enhanced efficacy and reduced dosing frequency, expanding therapeutic options for resistant viral infections.

Japan: Key Industry Developments (2025)

✅ June 2025: Shionogi submitted a supplemental NDA in Japan to expand ensitrelvir's indication to include treatment of COVID‐19 in pediatric patients aged 6 and older, along with a new pediatric‐friendly formulation tablet.

✅ September 2025: Shionogi's ensitrelvir NDA acceptance in the U.S. reinforces the drug's global strategic development and highlights Japan's leadership in novel antiviral therapies with cross‐border regulatory activity.

✅ October 2025: Japan's antiviral market context continues evolving with proactive responses to influenza and respiratory viruses regulatory and distribution systems were activated to support antiviral stocks in response to early influenza activity, demonstrating preparedness for viral outbreaks.

📌 Antiviral drugs Market 2025-26 M&A Deals

→ In November 2025, Merck & Co. agreed to acquire Cidara Therapeutics in an all‐cash deal valued at approximately $9.2 billion, paying $221.50 per share. Cidara develops CD388, a long‐acting influenza antiviral currently in late‐stage clinical development, and the acquisition strengthens Merck's antiviral and respiratory portfolio (expected close Q1 2026).

→ In December 2025, Mirum Pharmaceuticals entered into an agreement to acquire Bluejay Therapeutics for up to $820 million (including $250 M cash + $370 M stock + up to $200 M in milestones). Bluejay's pipeline includes brelovitug, an investigational monoclonal antibody targeting hepatitis D virus (HDV), marking a strategic addition to viral disease therapeutics.

Market Growth Drivers:-

• HIV/AIDS remains a major contributor to antiviral demand, with millions of patients requiring lifelong therapy.

• Hepatitis B and C infect hundreds of millions globally, necessitating extended antiviral regimens.

• Seasonal influenza and emerging zoonotic viruses create recurring demand spikes for effective therapeutics.

• Emerging viral threats and variants (i.e., SARS‐CoV‐2) have heightened both clinical urgency and public health prioritization for novel antivirals.

• Next‐generation antiviral formulations (e.g., RNA‐based therapies, long‐acting injectables) are gaining traction, extending therapeutic options beyond traditional small molecules.

• Artificial intelligence and big data are accelerating discovery cycles and reducing R&D costs by up to 30% in some reported use cases.

• Advances such as novel delivery systems and broad‐spectrum compounds expand effectiveness across multiple viral targets.

• A majority of leading pharmaceutical companies are expanding antiviral R&D budgets, with 75% of investments focused on next‐generation antivirals.

• Strategic alliances, M&A activities, and venture capital for infectious disease platforms have surged post‐COVID, fueling the introduction of novel compounds.

• Public sector funding and supportive policy frameworks (e.g., priority review designations) are shortening approval timelines and boosting market access.

📌 Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=antiviral-drugs-market?pratik

Antiviral drugs Market Major Players:-

Gilead Sciences, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, AbbVie, Merck & Co., Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, Dr. Reddy's Laboratories Ltd

Key players highlights:-

Gilead Sciences - Leading antiviral specialist known for HIV and hepatitis treatments such as Biktarvy and Harvoni.
Approx. 25% market share of the global antiviral drugs market.

GlaxoSmithKline plc (GSK) - Major player in HIV, influenza, and respiratory virus antivirals, leveraging its broad infectious disease portfolio.
Approx. 18% market share globally.

Merck & Co., Inc. - Strong presence in HIV and hepatitis antivirals with products like Isentress and Zepatier, plus expanding pipeline collaborations.
Part of the top 30-35% collective share with other leaders.

F. Hoffmann‐La Roche AG - Swiss pharmaceutical leader focusing on influenza and other viral therapies with global distribution strength.
Included in the core top market share group (30-35%).

Johnson & Johnson Services, Inc. (Janssen) - Contributes to antiviral market with key HIV regimens and broad commercial reach worldwide.
Also among the core group driving 30-35% combined market share.

Antiviral drugs Market Regional Highlights

North America
North America holds the largest share (around 43% of the global antiviral drugs market) driven by advanced healthcare systems and high R&D investment.
The U.S. dominates regional growth with strong pharmaceutical innovation, high infection prevalence (HIV, hepatitis, influenza), and favorable regulatory pathways boosting antiviral adoption.
Continuous expansion in antiviral drug approvals and public health initiatives sustains market leadership and reflects ongoing development focus.

Europe
Europe contributes about 27.23% of the global antiviral drugs market with steady growth supported by robust healthcare policies and sizable national pharmaceutical investments.
Key countries such as Germany, France, and the UK lead regional demand for advanced antiviral treatments and research.
The region's moderate growth is supported by streamlined regulatory processes and expanding antiviral R&D.

Asia Pacific
Asia Pacific accounts for around 24.45% of global antiviral market share and is the fastest-growing region due to rising healthcare access and viral disease burden.
China and India are significant contributors, driven by increasing biopharmaceutical manufacturing and expanding public health initiatives.
Growing investments in healthcare infrastructure and generic antiviral adoption further accelerate regional development.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/antiviral-drugs-market?pratik

Antiviral drugs Market Segment Analysis

The Global Antiviral Drugs Market is categorized based on several key segments. By drug class, it includes Reverse Transcriptase Inhibitors, which are further divided into Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), DNA Polymerase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, and other antiviral agents. By type, the market is segmented into branded and generic drugs, reflecting different pricing and accessibility. In terms of application, antivirals are used to treat HIV, hepatitis, herpes, influenza, and other viral infections. The end-user segment includes hospitals, clinics, and ambulatory surgical centers, representing the primary channels for drug administration. Finally, the market is analyzed by region, covering North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa, highlighting regional adoption trends and growth potential.

Antiviral drugs Market - FAQs

Q1: What is the current size of the Antiviral Drugs Market?
A: The market was valued at approximately USD 56 billion in 2023, driven by HIV, hepatitis, and influenza treatments.

Q2: What factors are driving growth in the Antiviral Drugs Market?
A: Increasing viral infections, R&D innovations, rising geriatric population, and expanded healthcare access are key growth drivers.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.